Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
048410.KQ Stock Summary
Top 10 Correlated ETFs
048410.KQ
In the News
048410.KQ Financial details
Company Rating
Sell
Market Cap
909.78B
Income
-14.5B
Revenue
9.48B
Book val./share
1137.24
Cash/share
296.72
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-52.97
Forward P/E
-
PEG
57.28
P/S
92.98
P/B
17.43
P/C
72.46
P/FCF
-85.33
Quick Ratio
2.17
Current Ratio
2.59
Debt / Equity
0.12
LT Debt / Equity
-
-
-
EPS (TTM)
-364.4
EPS next Y
-
EPS next Q
-
EPS this Y
-9.21%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-20.62%
Revenue Q/Q
-42.25%
EPS Q/Q
308.55%
-
-
-
-
SMA20
0.57%
SMA50
-11.87%
SMA100
-42.86%
Inst Own
-
Inst Trans
-
ROA
-29%
ROE
-31%
ROC
-0.32%
Gross Margin
53%
Oper. Margin
-170%
Profit Margin
-175%
Payout
-
Shs Outstand
39.82M
Shs Float
34.71M
-
-
-
-
Target Price
-
52W Range
17600.0-41200.0
52W High
-47.82%
52W Low
+22.16%
RSI
52.31
Rel Volume
1.16
Avg Volume
436.13K
Volume
506.81K
Perf Week
2.38%
Perf Month
-0.23%
Perf Quarter
-23.08%
Perf Half Y
-22.24%
-
-
-
-
Beta
1.193
-
-
Volatility
655.12%, 936.15%
Prev Close
2.38%
Price
21500
Change
0.7%
048410.KQ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 868.45 | 348.38 | 250.34 | 199.44 | 238.37 | |
Net income per share | 22.15 | -229.99 | -543.16 | -401.53 | -364.53 | |
Operating cash flow per share | 256.83 | 201.67 | -20.27 | -425.88 | -158.32 | |
Free cash flow per share | -120.31 | -500.12 | -122.17 | -465.09 | -173.1 | |
Cash per share | 203.65 | 535.04 | 601.35 | 475.84 | 296.96 | |
Book value per share | 1.36K | 1.46K | 1.67K | 1.48K | 1.14K | |
Tangible book value per share | 795.19 | 360.39 | 755.94 | 636.59 | 1.14K | |
Share holders equity per share | 1.36K | 1.46K | 1.67K | 1.48K | 1.14K | |
Interest debt per share | 409.74 | 1.05K | 496.15 | 169.07 | 146.54 | |
Market cap | 486.74B | 1048.68B | 932.12B | 1066.86B | 1042.13B | |
Enterprise value | 494.69B | 1066.6B | 938.42B | 1070.38B | 1045.87B | |
P/E ratio | 634.42 | -126.96 | -46.49 | -67.49 | -71.87 | |
Price to sales ratio | 16.18 | 83.82 | 100.86 | 135.88 | 109.91 | |
POCF ratio | 54.71 | 144.79 | -1.25K | -63.63 | -165.48 | |
PFCF ratio | -116.78 | -58.39 | -206.68 | -58.27 | -151.36 | |
P/B Ratio | 10.37 | 20.04 | 15.14 | 18.32 | 23.02 | |
PTB ratio | 10.37 | 20.04 | 15.14 | 18.32 | 23.02 | |
EV to sales | 16.44 | 85.25 | 101.54 | 136.33 | 110.31 | |
Enterprise value over EBITDA | 79.37 | -1.64K | -142.49 | -43.64 | -124.97 | |
EV to operating cash flow | 55.6 | 147.26 | -1.25K | -63.84 | -166.08 | |
EV to free cash flow | -118.69 | -59.38 | -208.07 | -58.46 | -151.9 | |
Earnings yield | 0 | -0.01 | -0.02 | -0.01 | -0.01 | |
Free cash flow yield | -0.01 | -0.02 | 0 | -0.02 | -0.01 | |
Debt to equity | 0.29 | 0.7 | 0.25 | 0.11 | 0.12 | |
Debt to assets | 0.21 | 0.39 | 0.19 | 0.09 | 0.1 | |
Net debt to EBITDA | 1.28 | -27.48 | -0.96 | -0.14 | -0.45 | |
Current ratio | 2.39 | 4.67 | 2.09 | 2.86 | 2.18 | |
Interest coverage | 3.13 | -3.92 | -3.09 | -58.64 | -31.17 | |
Income quality | 7.32 | -0.88 | 0.04 | 1.06 | 0.43 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.01 | 0 | 0 | |
Research and developement to revenue | 0.04 | 0.13 | 0.48 | 2.1 | 0.61 | |
Intangibles to total assets | 0.31 | 0.42 | 0.42 | 0.49 | 0 | |
Capex to operating cash flow | -1.47 | -3.48 | 5.03 | 0.09 | 0.09 | |
Capex to revenue | -0.43 | -2.01 | -0.41 | -0.2 | -0.06 | |
Capex to depreciation | -3.43 | -6.67 | -1.39 | -0.87 | -0.41 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 821.82 | 2.75K | 4.51K | 3.66K | 3.06K | |
ROIC | 0.04 | -0.05 | -0.12 | -0.39 | -0.19 | |
Return on tangible assets | 0.02 | -0.15 | -0.43 | -0.46 | -0.27 | |
Graham Net | 251.37 | -198.6 | 314.27 | 315.47 | 150.84 | |
Working capital | 19.32B | 32.89B | 18.2B | 15.63B | 8.22B | |
Tangible asset value | 27.55B | 12.94B | 27.91B | 25.06B | 45.27B | |
Net current asset value | 16.99B | 456.54M | 15.89B | 14.92B | 7.64B | |
Invested capital | 0.29 | 0.7 | 0.25 | 0.11 | 0.12 | |
Average receivables | 20.99B | 18.56B | 13.09B | 5.33B | 1.15B | |
Average payables | 608.64M | 502.96M | 184.89M | 439.16M | 558.62M | |
Average inventory | 5.13B | 5.15B | 3.78B | 3.15B | 2.77B | |
Days sales outstanding | 240.89 | 503.66 | 352.02 | 80.9 | 21.28 | |
Days payables outstanding | 16.22 | 7.22 | 9.06 | 42.44 | 28.26 | |
Days of inventory on hand | 119.12 | 170.86 | 158.47 | 182.1 | 169.92 | |
Receivables turnover | 1.52 | 0.72 | 1.04 | 4.51 | 17.15 | |
Payables turnover | 22.51 | 50.53 | 40.27 | 8.6 | 12.91 | |
Inventory turnover | 3.06 | 2.14 | 2.3 | 2 | 2.15 | |
ROE | 0.02 | -0.16 | -0.33 | -0.27 | -0.32 | |
Capex per share | -377.14 | -701.8 | -101.91 | -39.21 | -14.77 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 44.32 | 79.66 | 80.97 | 49.32 | 28.48 | |
Net income per share | -288.33 | -52.82 | -58.73 | -49.72 | -203.13 | |
Operating cash flow per share | -139.5 | -59.94 | -14.71 | -52.44 | -31.28 | |
Free cash flow per share | -146.91 | -72.71 | -15.3 | -53.11 | -32.05 | |
Cash per share | 484.57 | 414.63 | 391.8 | 336.7 | 296.72 | |
Book value per share | 1.51K | 1.44K | 1.39K | 1.34K | 1.14K | |
Tangible book value per share | 648.28 | 601.91 | 557.58 | 513.18 | 1.14K | |
Share holders equity per share | 1.51K | 1.44K | 1.39K | 1.34K | 1.14K | |
Interest debt per share | 162.61 | 155.87 | 141.56 | 147.54 | 140.04 | |
Market cap | 1047.62B | 819.72B | 1058.55B | 1170.24B | 1042.96B | |
Enterprise value | 1051.13B | 822.43B | 1059.59B | 1172.83B | 1046.7B | |
P/E ratio | -23.5 | -97.73 | -113.23 | -147.83 | -32.25 | |
Price to sales ratio | 611.48 | 259.21 | 328.52 | 596.11 | 919.96 | |
POCF ratio | -194.27 | -344.5 | -1.81K | -560.61 | -837.73 | |
PFCF ratio | -184.47 | -283.99 | -1.74K | -553.61 | -817.41 | |
P/B Ratio | 17.99 | 14.38 | 19.18 | 21.93 | 23.04 | |
PTB ratio | 17.99 | 14.38 | 19.18 | 21.93 | 23.04 | |
EV to sales | 613.53 | 260.07 | 328.84 | 597.43 | 923.26 | |
Enterprise value over EBITDA | -100.57 | -441.77 | -679.98 | -703.03 | -319.06 | |
EV to operating cash flow | -194.92 | -345.64 | -1.81K | -561.85 | -840.73 | |
EV to free cash flow | -185.09 | -284.93 | -1.74K | -554.83 | -820.34 | |
Earnings yield | -0.01 | 0 | 0 | 0 | -0.01 | |
Free cash flow yield | -0.01 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.11 | 0.11 | 0.1 | 0.11 | 0.12 | |
Debt to assets | 0.09 | 0.09 | 0.09 | 0.09 | 0.1 | |
Net debt to EBITDA | -0.34 | -1.46 | -0.67 | -1.55 | -1.14 | |
Current ratio | 2.86 | 2.83 | 2.95 | 2.59 | 2.18 | |
Interest coverage | -137.28 | -30.08 | -25.54 | -20.1 | -58.04 | |
Income quality | 0.48 | 1.13 | 0.25 | 1.05 | 0.15 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 2.63 | 0.66 | 0.42 | 0.6 | 1.05 | |
Intangibles to total assets | 0.49 | 0.5 | 0.53 | 0.54 | 0 | |
Capex to operating cash flow | 0.05 | 0.21 | 0.04 | 0.01 | 0.02 | |
Capex to revenue | -0.17 | -0.16 | -0.01 | -0.01 | -0.03 | |
Capex to depreciation | -0.73 | -1.17 | -0.06 | -0.08 | -0.13 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.13K | 1.31K | 1.35K | 1.22K | 2.28K | |
ROIC | -0.17 | -0.04 | -0.03 | -0.03 | -0.07 | |
Return on tangible assets | -0.33 | -0.06 | -0.08 | -0.07 | -0.15 | |
Graham Net | 321.27 | 288.33 | 284.9 | 228.75 | 150.72 | |
Working capital | 15.63B | 14.37B | 13.16B | 11.43B | 8.22B | |
Tangible asset value | 25.06B | 23.89B | 22.19B | 20.43B | 45.27B | |
Net current asset value | 14.92B | 13.61B | 13B | 11.16B | 7.64B | |
Invested capital | 0.11 | 0.11 | 0.1 | 0.11 | 0.12 | |
Average receivables | 5.13B | 2.37B | 2.59B | 2.45B | 1.64B | |
Average payables | 759.23M | 675.99M | 576.48M | 567.83M | 539.25M | |
Average inventory | 2.62B | 2.84B | 2.38B | 2.16B | 2.43B | |
Days sales outstanding | 91.42 | 85.1 | 60.93 | 124.74 | 43.88 | |
Days payables outstanding | 47.21 | 34.85 | 25.44 | 48.86 | 42.01 | |
Days of inventory on hand | 202.55 | 143.05 | 106.28 | 171.84 | 252.54 | |
Receivables turnover | 0.98 | 1.06 | 1.48 | 0.72 | 2.05 | |
Payables turnover | 1.91 | 2.58 | 3.54 | 1.84 | 2.14 | |
Inventory turnover | 0.44 | 0.63 | 0.85 | 0.52 | 0.36 | |
ROE | -0.19 | -0.04 | -0.04 | -0.04 | -0.18 | |
Capex per share | -7.41 | -12.77 | -0.58 | -0.66 | -0.78 |
048410.KQ Frequently Asked Questions
What is Hyundai Bioscience Co., Ltd. stock symbol ?
Hyundai Bioscience Co., Ltd. is a KR stock and trading under the symbol 048410.KQ
What is Hyundai Bioscience Co., Ltd. stock quote today ?
Hyundai Bioscience Co., Ltd. stock price is $21500 today.
Is Hyundai Bioscience Co., Ltd. stock public?
Yes, Hyundai Bioscience Co., Ltd. is a publicly traded company.